民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2023年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所上市公司自律监管指引第11号——持续督导》 等有关法律、法规的规定，民生证券股份有限公司（以下简称"民生证券" 或"保荐机构"）作为杭州安旭生物科技股份有限公司（以下简称"安旭生 物"或"公司"）持续督导工作的保荐机构，负责安旭生物上市后的持续督导 工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 | 序号 | 工作情况 | 持续督导情况 | | --- | --- | --- | | 1 | | 保荐机构已建立健全并有效执 行了持续督导制度，并制定了相 | | | 建立健全并有效执行持续督导工作制度，并针对 | | | | 具体的持续督导工作制定相应的工作计划 | 应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始 | 保荐机构已与安旭生物签订《保 | | | 前，与上市公司或相关当事人签署持续督导协 | 荐协议》，该协议明确了双方在 | | | 议，明确双方在持续督导期间的权利义务，并报 | 持续 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a year-on-year growth of 25%[1] - The company's revenue for the first half of 2023 was ¥204,374,691.10, a decrease of 96.55% compared to ¥5,929,966,318.96 in the same period last year[22] - The net profit attributable to shareholders for the first half of 2023 was ¥166,775,151.34, down 94.20% from ¥2,877,509,384.95 year-on-year[22] - The net cash flow from operating activities decreased by 117.48%, resulting in a negative cash flow of ¥687,338,036.15[24] - The net profit after deducting non-recurring gains and losses decreased by 96.53% to ¥99,115,401.45 from ¥2,854,617,836.86 in the same period last year[22] - The significant decline in revenue and profit is attributed to the end of the global respiratory infectious disease, leading to a substantial decrease in market demand for related testing products[24] - The company achieved operating revenue of 204.37 million yuan in the first half of 2023, a decrease of 96.55% compared to the same period last year[69] - The net profit attributable to the parent company was 166.78 million yuan, down 94.20% year-on-year[69] - The total assets reached 6.26 billion yuan, a year-on-year decrease of 9.83%[69] Research and Development - The company is investing in R&D, with a budget increase of 30% for new technology development[1] - The proportion of R&D investment to revenue increased to 23.65%, up by 12.62 percentage points compared to 11.03% in the previous year[23] - The total R&D expenditure for the period was ¥48,338,587.79, a significant decrease of 92.61% compared to the same period last year, while the proportion of R&D expenditure to operating income increased by 12.62%[54][55] - The company has developed over 200 types of colloidal gold products, demonstrating strong technical capabilities in colloidal gold immunochromatography technology, with high sensitivity and specificity[39] - The fluorescence immunochromatography technology platform has developed nearly 60 product varieties, with sensitivity improved by 5-10 times compared to traditional methods[40] - The company is actively developing new products in the fields of molecular diagnostics and mass spectrometry, aiming for rapid on-site testing applications[45] - The company has completed the development of 17 new products, with 4 of them being allergy testing series widely used in various medical institutions[57] - The company has 21 ongoing research projects in chronic disease testing, with 7 projects already completed and ready for market[57] - The company has 9 ongoing research projects related to immunoassay and automation systems, with 1 project already completed[59] Market Expansion and Strategy - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20%[1] - New product launches are expected to contribute an additional 10% to overall revenue in the upcoming quarters[1] - Market expansion plans include entering three new international markets by the end of 2023[1] - The company is considering strategic acquisitions to enhance its product portfolio and market presence[1] - The company is focusing on expanding its market presence through new product development and strategic partnerships in the diagnostics field[58] - The company launched the international pet diagnostic brand AlievePet in April 2023, covering 80 types of detection projects[71] - The company has established a marketing network with subsidiaries in the US, Singapore, and Hong Kong, and has formed a marketing matrix in major Chinese cities, aiming for a dual growth strategy in domestic and international markets[75] Risks and Challenges - The company has identified potential risks, including regulatory changes that could impact operations[1] - The company faces risks related to market competition, particularly in the in vitro diagnostics industry, which may impact growth and profitability if it cannot maintain its competitive edge[80] - The company is exposed to foreign exchange risks, as 84.10% of its revenue is generated from exports, primarily settled in USD, making it vulnerable to RMB exchange rate fluctuations[86] Corporate Governance and Compliance - The board confirmed that there are no significant governance issues affecting the integrity of the financial report[1] - The company has not reported any significant changes in its environmental information disclosure during the reporting period[115] - The company has not disclosed any updates on employee stock ownership plans or other incentive measures during the reporting period[112] - The company has committed to ensuring that any unavoidable related transactions will be conducted under normal commercial conditions and comply with legal requirements[144] Shareholder Information - The company has committed to a 36-month lock-up period for major shareholders following the IPO, ensuring stability in shareholding[117] - The actual controllers, Ling Shisheng and Jiang Xueying, have similar commitments regarding share lock-up and extensions under the same conditions as Aixi Holdings[120] - The company ensures that any share reduction after the lock-up period will not exceed 25% of the total shares held[128] - The company will compensate investors for any losses caused by its failure to fulfill commitments[26] Environmental and Social Responsibility - The company invested 195.3 million yuan in environmental protection during the reporting period[114] - The company has implemented carbon reduction measures, focusing on low-carbon energy use and resource recycling in daily operations and future production facilities[115] - The company has received multiple honors for its social responsibility efforts, including contributions to the Hangzhou Asian Games and various labor awards[77]

证券代码：688075 证券简称：安旭生物 公告编号：2023-025 杭州安旭生物科技股份有限公司 关于参加 2023 半年度医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 说明会类型 本次投资者说明会以视频和网络互动形式召开，公司将针对 2023 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 会议线上交流时间：2023 年 9 月 5 日(星期二) 下午 13:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心 二、 说明会召开的时间、方式 （一） 会议线上交流时间：2023 年 9 月 5 日(星期二) 下午 13:00-15:00 （二） 会议召开方式：视频和线上文字互动 （三） 视频和线上文字互动平台：上海证券交易所上证路演中心 （http://roadshow.sseinfo.com/） 重要内容提示： （http://roads ...

Corporate Structure and Management - The company has 13 first-level subsidiaries and 3 second-level subsidiaries, all managed under a centralized group management system[2] - The company's internal control system was deemed effective by the audit firm ShineWing, with no significant deficiencies reported[3] - The company has established a flat management structure to facilitate communication and feedback between employees and management[23] - The company elected Dong Wenkun and Huang Yinqian as non-independent directors for the second board of directors[109] - The company elected Zhang Guobiao, Zhou Juanying, and Ma Weimin as independent directors for the second board of directors[109] - The company elected Hong Yuyan and Zhou Lala as non-employee representative supervisors for the second board of supervisors[109] - Ling Shisheng, Chairman and CEO, holds 22,806,800 shares at the end of the year, an increase of 7,396,800 shares due to equity distribution[111] - Jiang Xueying, Vice Chairman and Deputy General Manager, holds 1,817,736 shares at the end of the year, an increase of 589,536 shares due to equity distribution[111] - The total number of shares held by directors, supervisors, and senior management increased by 7,986,336 shares to 24,624,536 shares at the end of the year[114] - Ling Shisheng has been the Chairman and CEO since August 2019, with extensive experience in the biotech industry[114] - Jiang Xueying has been the Vice Chairman and Deputy General Manager since April 2022, with a background in law and corporate management[114] - Dong Wenkun has been the Director, Deputy General Manager, and R&D Director since August 2019, with a strong background in biotech R&D[114] - Huang Yinqian has been the Director and Production Operations Director since August 2019, with experience in quality management and production operations[114] - Wu Yahong stepped down as CFO on December 26, 2022, but continued as Board Secretary until March 6, 2023, when Han Jun was appointed as the new Board Secretary[116][117] - Kang Min was appointed as CFO on December 26, 2022, following Wu Yahong's resignation[116] Environmental and Social Responsibility - The company invested 1.0225 million RMB in environmental protection during the reporting period[5] - The company did not directly emit greenhouse gases but consumed electricity, falling under the category of equivalent greenhouse gas emissions[8] - The company's main energy consumption includes water, electricity, and natural gas, supplied by local authorities[9] - The company reduced carbon emissions by implementing low-carbon measures in office operations, R&D, and future production base construction[13] - The company donated 849,100 RMB in cash and 5.7387 million RMB in materials for public welfare activities, including donations to educational foundations and the 2022 Asian Games Organizing Committee[14] - The company contributed 50,000 RMB to rural revitalization efforts, specifically donating to Anji County Fourth Primary School[17] - The company strictly adheres to environmental laws and regulations, ensuring compliance with emission standards and waste management[12] - The company actively participated in social responsibility initiatives, including poverty alleviation and rural revitalization projects[17] - The company donated antigen products to multiple regions and institutions, including Hangzhou Shangcheng District, Changchun City in Jilin Province, and Hong Kong, and has been awarded the title of "Love Enterprise" by the Red Cross Society of Shangcheng District, Hangzhou[153] Financial Performance and Dividends - The company plans to distribute a cash dividend of 50 yuan per 10 shares, totaling 453,867,160.00 yuan (including tax), accounting for 14.91% of the net profit attributable to shareholders in 2022[29] - The company intends to increase its share capital by 4 shares per 10 shares through capital reserve, resulting in a total share capital increase to 127,082,805 shares[29] - The company's full-year revenue for 2022 reached RMB 3.45 billion, representing a year-over-year growth of 28.5%[35] - Net profit for 2022 was RMB 1.23 billion, an increase of 35.2% compared to the previous year[35] - The company's gross margin improved to 65.8% in 2022, up from 62.3% in 2021[35] - Revenue in 2022 increased by 287.97% year-on-year to RMB 6,165,884,330.92, driven by market recognition of the company's high-quality testing products and expanded sales scale[43][44] - Net profit attributable to shareholders of the listed company surged by 312.26% year-on-year to RMB 3,044,673,309.82, in line with the significant revenue growth[43][44] - Net cash flow from operating activities rose by 453.79% year-on-year to RMB 3,743,278,071.62, primarily due to increased revenue and corresponding collections[43][44] - Shareholders' equity attributable to the listed company grew by 108.02% year-on-year to RMB 5,421,936,037.32, mainly due to increased retained earnings from profitability[43][48] - Total assets increased by 111.61% year-on-year to RMB 6,941,682,206.33, driven by higher asset investments and improved sales collections[43][48] - Basic earnings per share (EPS) and diluted EPS both increased by 217.91% year-on-year to RMB 33.54, reflecting higher profitability[43][48] - Revenue for 2022 reached 61.66 billion yuan, a year-on-year increase of 287.97%[56] - Net profit attributable to the parent company was 30.45 billion yuan, up 312.26% year-on-year[56] - Total assets at the end of 2022 were 69.42 billion yuan, an increase of 111.61% compared to the previous year[56] - Equity attributable to the parent company was 54.22 billion yuan, up 108.02% year-on-year[56] - Revenue for 2022 reached 61.66 billion yuan, a year-on-year increase of 287.97%[85] - Net profit attributable to the parent company was 30.45 billion yuan, up 312.26% year-on-year[85] - Overseas sales accounted for 99.14% of total revenue, with foreign exchange gains of 511.65 million yuan[78] - Accounts receivable at the end of the reporting period stood at 253.20 million yuan, with 98.06% within one year[79] - Total assets increased by 111.61% to 69.42 billion yuan by the end of 2022[85] - Equity attributable to the parent company rose by 108.02% to 54.22 billion yuan[85] - Sales expenses surged by 1,500.69% to 493.76 million yuan[86] - Financial expenses decreased by 2,411.41% to -533.59 million yuan, primarily due to foreign exchange gains[86] - Revenue from the in vitro diagnostics industry reached 6.165 billion yuan, a year-on-year increase of 287.97%, with a gross margin of 74.78%, an increase of 9.34 percentage points[175] - Revenue from infectious disease testing products was 5.851 billion yuan, a year-on-year increase of 334.60%, with a gross margin of 76.88%, an increase of 7.75 percentage points[175] - Revenue from the North American market was 4.611 billion yuan, a year-on-year increase of 503.09%, with a gross margin of 78.02%, an increase of 9.08 percentage points[176] - Revenue from the ODM sales model was 5.017 billion yuan, a year-on-year increase of 1,524.85%, with a gross margin of 77.14%, an increase of 12.16 percentage points[176] - Production volume of diagnostic reagents reached 85,996.95 thousand units, a year-on-year increase of 186.85%, while sales volume was 77,539.86 thousand units, a year-on-year increase of 173.79%[177] - Direct material costs for the in vitro diagnostics industry were 984.12 million yuan, accounting for 63.29% of total costs, a year-on-year increase of 132.73%[180] - Direct labor costs for the in vitro diagnostics industry were 429.67 million yuan, accounting for 27.63% of total costs, a year-on-year increase of 396.76%[180] - Sales expenses increased by 1,500.69% to 493,759,585.28 yuan due to increased personnel bonuses and promotion expenses[190] - R&D expenses increased by 367.57% to 329,074,506.45 yuan due to continued investment in new product and technology platform development[190] - Net cash flow from operating activities increased by 453.79% to 3,743,278,071.62 yuan due to performance growth[192] - Net cash flow from investing activities decreased by 1,113.13% to -3,614,291,753.32 yuan due to increased fixed asset investment and financial product investments[192] - Trading financial assets increased by 99.99% to 1,405,975,108.31 yuan, accounting for 20.25% of total assets, due to increased bank wealth management investments[194] - Other current assets increased by 30.19% to 2,095,408,384.90 yuan, mainly due to increased bank deposits and time deposit business[195] - Fixed assets increased by 4.9% to 339,937,052.68 yuan, driven by higher investments in equipment and factory buildings[195] - Construction in progress rose by 1.32% to 91,421,013.58 yuan, attributed to increased investment in fundraising projects[195] - Lease assets increased by 0.65% to 44,809,541.95 yuan due to the expansion of leased factory space[195] - Intangible assets grew by 0.60% to 41,586,011.03 yuan, mainly from land payments and software system investments[195] - Deferred tax assets surged by 2.09% to 145,301,308.85 yuan, driven by inventory depreciation and fixed asset impairment provisions[195] - Short-term borrowings increased by 0.13% to 2,000,000 yuan, related to bank loans for company acquisitions[195] - Accounts payable rose by 57.01% to 868,209,160.64 yuan, reflecting higher order volumes[195] - Contract liabilities decreased by 208.65% to 32,248,087.64 yuan, due to a decline in sales and prepayments[195] - Investment amount for the reporting period was 24,200,000 yuan[200] Research and Development - Research and development expenses increased by 22.7% to RMB 450 million, accounting for 13% of total revenue[35] - The company successfully obtained FDA 510(k) clearance for 3 new IVD products during the reporting period[34] - The company launched 12 new POCT products in 2022, contributing to a 15% increase in product portfolio[35] - R&D expenditure as a percentage of revenue increased by 0.91 percentage points year-on-year to 5.34%, indicating continued investment in innovation[43] - The company obtained 9 new domestic medical device registrations/filings in 2022[57] - The company obtained 1 new international medical device registration in Canada in 2022[57] - The company's R&D investment in 2022 increased by 367.57% year-on-year, reaching a total of 329,074,506.45 yuan[60] - The proportion of R&D investment to operating income in 2022 was 5.34%, an increase of 0.91 percentage points compared to the previous year[60] - The significant increase in R&D investment is attributed to the company's continued focus on new product development, registration, and new technology platform projects[61] - The company obtained multiple certifications for COVID-19 antigen nasal test kits in Australia, with a total of 372,335 units certified[58] - The company received EU CE certification for its HIV rapid test device, COVID-19 & Influenza A/B antigen nasal test kit, and COVID-19 antigen saliva test kit[58] - The company obtained ANVISA certification in Brazil for RSV test, Norovirus test, H.pylori Ag test, and H.pylori Ab test kit[58] - The company received EU CE certification for Monkeypox antibody and antigen rapid test devices, as well as Monkeypox nucleic acid detection kits[58] - The company obtained ANVISA certification in Brazil for Strep A test, Malaria test, FOB test, Flu A/B rapid test, Gonorrhea rapid test, Zika rapid test, and HbsAg rapid test[59] - The company received certifications in Guatemala for Rotavirus and Adenovirus combined test, Dengue virus test, H.pylori test, Syphilis test, and Multidrug test panels[59] - The company has 60 R&D projects, with 40 completed and the rest in various stages of development, focusing on areas such as POCT clinical testing, food safety testing, and judicial testing[63] - The company's R&D personnel increased to 286, accounting for 30.11% of the total workforce, with a total R&D salary of 4764.67 million yuan[64] - The company's core competitiveness lies in its technological innovation, with a focus on POCT reagents and instruments, covering eight major fields including drug detection, infectious disease detection, and chronic disease detection[66] - The company has a strong capability in core biological raw material preparation, with 37 antigen and antibody raw material R&D projects, of which 25 have been completed[67] - The company's R&D and core technology advantages include a diverse team of professionals and a dual-driven development model focusing on market demand and technological innovation[68] - The company has a comprehensive product line and efficient product iteration, with a focus on infectious disease detection products and a complete technology platform[69] - The company emphasizes quality and brand advantages, adhering to strict quality control and building a strong brand presence both domestically and internationally[70] - The company's core management team has extensive experience and expertise in the POCT industry, driving product differentiation and technological innovation[71] - The company has established six major technology platforms, including a new biopharmaceutical platform, and has formed an integrated industrial chain layout of raw materials, reagents, and instruments[144] - The company has developed a series of "pen-type" products for respiratory infectious disease detection, including COVID-19, influenza A/B, and multi-plex detection, and has expanded this technology to other global infectious diseases such as HIV, dengue, and malaria[144] - The company has launched a comprehensive home health management solution, covering prevention, early screening, and post-treatment monitoring, with products for blood glucose, lipids, hemoglobin, myocardial health, and female physiological health[145] - The company has obtained 102 new authorized patents, including 3 invention patents and 11 utility model patents, and has accumulated a total of 212 authorized patents[145] - The company has received 37 new certifications, including 28 international certifications, bringing the total number of certifications to 175[145] - The company has established an industrial investment fund, Hangzhou Chuanxu Equity Investment Partnership, focusing on early-stage and growth-stage projects in pharmaceuticals, healthcare, and biopharmaceuticals[146] - The company has acquired 100% equity of Hunan Tianzong and Hunan Dayou, and established overseas subsidiaries in Singapore and the United States to support its healthcare industry development[146] - The company has set up a medical testing laboratory to conduct molecular diagnostic projects, including respiratory pathogen gene detection, infectious virus detection, and non-invasive prenatal screening[146] - The company has collaborated with universities such as Zhejiang Gongshang University, Zhejiang University City College, and Zhejiang University to establish research centers and introduce advanced scientific talent[147] - The company has strengthened the progress control of two provincial key projects: the fully automated testing integrated machine and ultra-high sensitivity Listeria monocytogenes detection kit development project, and the research and application project of multiple non-crosstalk fluorescent encoding microspheres for bio-liquid chips[148] - The company has established local companies in Singapore and the United States, and set up research and sales centers in key domestic cities including Beijing, Nanjing, Chengdu, Changsha, and Wuxi, focusing on domestic network layout[150] - The company has completed the integration of the entire upstream and downstream supply chain, achieving three self-controllable aspects: core raw materials, key equipment, and key technologies[151] - The company has optimized the cost structure and accelerated the pace of machine replacement, developing and testing the fourth-generation equipment of intelligent manufacturing production lines[151] - The company has successfully launched the ERP system, initiating the digital management upgrade and building a unified enterprise resource control platform[152] - The company has mastered gene engineering recombinant antigen technology, synthetic antigen technology, polyclonal antibody preparation technology, and monoclonal antibody preparation technology, achieving partial self-supply of nearly 100 products required antigens and antibodies, accounting for more than half of the company's biological raw material demand[158] - The company has formed a complete research, development, and innovation system, continuously iterating and improving products based on market and customer needs, and actively researching industry development trends to develop new products with foresight[163] Market and Industry Analysis - International sales accounted for 45% of total revenue, with significant growth in European and North American markets[35] - The company completed the acquisition of Hunan Tianzong Yijun Biotech, expanding its presence in the Chinese domestic market[34] - The company faces risks from intensified competition and potential market share loss[75] - New EU IVDR regulations may impact the company's ODM business in Europe[82] - The global IVD market in 2022 was valued at 127.4 billion USD, with the POCT segment (excluding diabetes) accounting for 28.7 billion USD, or 22.5% of the market[93] - The company plans to expand production capacity, upgrade existing products, and enhance automation to improve efficiency and scale[96] - The company aims to increase its market share

Financial Performance - The company's operating revenue for 2022 reached RMB 6,165,884,330.92, representing a 287.97% increase compared to RMB 1,589,279,102.40 in 2021[23]. - The net profit attributable to shareholders of the listed company was RMB 3,044,673,309.82, up 312.26% from RMB 738,526,270.09 in the previous year[23]. - The net cash flow from operating activities was RMB 3,743,278,071.62, reflecting a significant increase of 453.79% compared to RMB 675,939,933.45 in 2021[23]. - The total assets at the end of 2022 amounted to RMB 6,941,682,206.33, an increase of 111.61% from RMB 3,280,443,711.10 at the end of 2021[23]. - The basic earnings per share for 2022 was RMB 33.54, a 217.91% increase from RMB 10.55 in 2021[23]. - The net profit excluding non-recurring gains and losses was 2,983.54 million RMB, up 310.42% from the previous year[36]. - The company achieved a revenue of 6,165.88 million RMB, representing a growth of 287.97% compared to the same period last year[36]. - The company reported a gross margin of 60%, reflecting improved operational efficiency and cost management[86]. Research and Development - The R&D expenditure as a percentage of operating revenue was 5.34%, up from 4.43% in 2021, indicating a focus on innovation[23]. - The total R&D investment for the year reached ¥329,074,506.45, a significant increase of 367.57% compared to ¥70,379,805.36 in the previous year[95]. - The company has focused on enhancing R&D for new products and technology platforms, leading to the substantial increase in R&D expenditures[96]. - The company has developed over 200 types of colloidal gold products, achieving high sensitivity, strong specificity, and good stability in drug detection, infectious disease detection, pregnancy detection, tumor detection, and myocardial detection[73]. - The company has established a new research and development technology platform for recombinant antibodies and bioactive enzymes, enhancing its product development capabilities[77]. - The company is actively pursuing new technology platforms to support its product development initiatives[96]. Market Expansion and Strategy - The company is committed to expanding its market presence and enhancing its product offerings through ongoing research and development efforts[23]. - The company focused on expanding its market share both domestically and internationally, aiming to become a leader in the POCT industry[35]. - Future guidance indicates an expected revenue growth of 20% for 2023, driven by new product launches and market expansion efforts[86]. - The company is exploring acquisition opportunities to bolster its product portfolio and expand its technological capabilities[87]. - The company aims to enhance market share by integrating existing technological resources and expanding through self-research, collaboration, or acquisitions in the biomedical health industry[167]. - The company is focusing on the industrialization of its chemiluminescence technology platform and precision detection platform, aiming for single-use POCT chemiluminescence technology[162]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[9]. - The independent directors have been actively involved in overseeing the company's strategic direction and governance[179]. - The company has a history of management changes, with several key personnel transitions noted in the reports[184]. - The board of directors has been restructured to enhance operational efficiency and oversight[184]. - The company established a compensation and assessment committee to develop performance evaluation standards and compensation plans based on industry benchmarks[187]. - The company is committed to strict compliance with the Company Law and regulatory rules during all committee meetings, ensuring diligent and responsible governance[200]. Risk Management - The company has outlined potential risk factors that could significantly impact its operations in the "Management Discussion and Analysis" section[4]. - The company faced risks related to quality control across various stages of production, including procurement and storage[113]. - The company is exposed to exchange rate fluctuations, with foreign exchange gains reported at CNY 51,165,270.00 during the reporting period[114]. - The company's gross profit margin may face volatility due to increased market competition and pricing strategies[116]. - The company's future performance is uncertain due to the dependency on the overseas sales of COVID-19 rapid test products[120]. Shareholder Information - The company plans to distribute a cash dividend of 50 RMB (including tax) for every 10 shares, totaling 453,867,160 RMB, which accounts for 14.91% of the net profit attributable to shareholders in 2022[6]. - The company reported a total shareholding increase from 16,638,200 to 24,624,536, representing an increase of 7,986,336 shares[179]. - The chairman and general manager, Ling Shisheng, increased his shareholding from 15,410,000 to 22,806,800, an increase of 7,396,800 shares[177]. - The total pre-tax remuneration for the chairman was reported at 656.11 million yuan[177]. - The company aims to enhance shareholder value through effective management and strategic initiatives[179]. Product Development and Innovation - The company has launched several new products, including a blood glucose and uric acid analyzer and a multifunctional testing device, which received regulatory approvals[92]. - The company is committed to advancing its research and development efforts, as evidenced by the numerous new patents and software registrations filed during the year[90]. - The company has introduced a range of new diagnostic tests, including those for HIV, RSV, and monkeypox, enhancing its market offerings[93][94]. - The company has established six major technology platforms in the field of precision medical diagnostics, including a newly added biopharmaceutical platform, enhancing its industrial chain layout[37]. - The company has developed a self-supply plan for core raw materials, achieving over 50% self-sufficiency in biological raw materials, which supports continuous innovation and stable production[51]. Social Responsibility - The company has actively engaged in social responsibility initiatives, donating antigen products to various regions and supporting local education[46]. - The company is committed to increasing self-sufficiency in core raw materials to reduce costs and enhance competitiveness[164].

Financial Performance - The company's operating revenue for Q1 2023 was ¥121,477,537.33, representing a decrease of 97.78% compared to the same period last year[3] - The net profit attributable to shareholders was ¥50,831,559.77, down 98.10% year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥8,359,409.24, reflecting a decline of 99.69% compared to the previous year[3] - Basic and diluted earnings per share were both ¥0.56, down 98.10% from the same period last year[3] - Total operating revenue for Q1 2023 was ¥121,477,537.33, a significant decrease from ¥5,474,543,757.08 in Q1 2022[19] - Net profit for Q1 2023 was ¥50,378,384.59, compared to ¥2,681,700,014.97 in Q1 2022, indicating a substantial decline[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.56, a sharp drop from ¥29.54 in Q1 2022[21] Cash Flow - The net cash flow from operating activities was -¥119,997,845.24, a decrease of 103.30% year-over-year[3] - In Q1 2023, the net cash flow from operating activities was -119,997,845.24, a significant decrease compared to 3,631,925,330.95 in Q1 2022[24] - Total cash inflow from operating activities was 306,265,340.17, down from 4,867,104,534.58 in the same period last year[24] - Cash outflow from operating activities reached 426,263,185.41, compared to 1,235,179,203.63 in Q1 2022[24] - The net cash flow from investment activities was -1,219,506,435.64, an improvement from -3,762,403,576.95 in Q1 2022[25] - Cash inflow from investment activities totaled 3,441,647,758.17, up from 239,645,141.51 in the previous year[25] - Cash outflow from investment activities was 4,661,154,193.81, compared to 4,002,048,718.46 in Q1 2022[25] - The net cash flow from financing activities was -11,506.16, compared to -2,480,000.00 in Q1 2022[26] - The ending cash and cash equivalents balance was 794,525,554.37, down from 1,907,634,230.41 at the end of Q1 2022[26] - The company reported a significant decrease in cash received from operating activities, with a drop of approximately 93.7% year-over-year[24] - The company experienced a cash outflow of 1,343,634,889.25 in Q1 2023, compared to a smaller outflow of 139,575,147.11 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,943,063,580.71, a slight increase of 0.02% from the end of the previous year[4] - Total current assets as of March 31, 2023, amounted to ¥6,248,634,020.11, a slight increase from ¥6,206,106,624.28 at the end of 2022[15] - Total liabilities for Q1 2023 were ¥1,451,715,121.80, down from ¥1,522,910,864.17 in the previous period[17] - The company's total equity as of Q1 2023 was ¥5,491,348,458.90, compared to ¥5,418,771,342.16 previously[17] Research and Development - Total R&D investment amounted to ¥23,771,592.09, a decrease of 95.72% compared to the previous year[3] - The proportion of R&D investment to operating revenue increased by 9.43 percentage points to 19.57%[3] - Research and development expenses for Q1 2023 were ¥23,771,592.09, significantly lower than ¥555,198,928.03 in Q1 2022[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,831[11] - The top ten shareholders collectively hold 59.79% of the company's shares, with the largest shareholder, Hangzhou Aixi Holdings, owning 26.87%[11] - The company distributed a cash dividend of ¥3.88 per share, with a capital reserve increase of 0.48 shares for every share held[12] Other Information - The company has engaged in securities lending, with a total of 106,100 shares lent out, leaving 801,637 shares held as restricted stock[12] - The company is focused on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[13] - Other comprehensive income after tax for Q1 2023 was ¥8,357,524.90, compared to ¥2,589,324.05 in Q1 2022[21] - The company reported an investment income of ¥42,938,603.12 for Q1 2023, a notable increase from ¥137,100.00 in the previous period[20]

二、 说明会召开的时间、地点 证券代码：688075 证券简称：安旭生物 公告编号：2023-015 杭州安旭生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 04 月 29 日(星期六) 至 05 月 09 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jun.yu@diareagent.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 杭州安旭生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年年度报告、2023 年第一季度报告及 2022 年度利润分配及资 本公积转增股本预案的公告，为便于广大投资者更全面深入地了解公司 2022 年 度和 2023 年第一季度的经营成果、财务状况及现金分红情况，公司计划于 2023 年 05 月 10 日 上午 09:00-10:00 举行 ...

杭州安旭生物科技股份有限公司 投资者关系活动记录表 证券简称：安旭生物 证券代码：688075 编号：2022-004 | --- | --- | --- | |-----------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 □媒体采访 | | 投资者关系 活动类别 | □业绩说明会 | □新闻发布会 □路演活动 | | | 现场参观 | □其他（电话会议） | | | 国信证券 超、王文韬 | 李伟波、苏于、许瑶佳、马彩利、方丹、毛静、劳世 | | | 君弘资产 | 郑确、苏颖 君颐资产 娄志刚 | | 参与单位名 | 盛元资本 | 许柳、沈萍 礼翰投资 罗杭婷 | | | 长添资产 童鸿 | 正帛资产 楼浩 | | | 敦敏资产 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥196,648,169.86, representing a year-over-year increase of 4.62%[5] - The net profit attributable to shareholders for Q3 2022 reached ¥254,666,293.91, a significant increase of 211.38% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥248,696,376.94, up 209.48% year-over-year[5] - Total operating revenue for the first three quarters of 2022 reached CNY 6,126,614,488.82, a significant increase from CNY 681,989,024.08 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was CNY 3,131,740,429.19, a substantial rise from CNY 283,904,582.25 in 2021[21] - The company reported a total comprehensive income of CNY 3,183,109,146.63 for the third quarter of 2022, up from CNY 284,351,161.66 in the same quarter of 2021[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,608,601,462.05, reflecting a 131.94% increase from the end of the previous year[6] - The company's total liabilities reached CNY 2,060,066,724.14, while total equity was CNY 5,548,534,737.91[19] - The company’s total assets amounted to approximately ¥7.61 billion, compared to ¥3.28 billion at the end of 2021[17] - The company’s inventory increased to approximately ¥429.39 million from ¥243.35 million year-over-year[17] - The company’s fixed assets were valued at approximately ¥477.78 million, up from ¥139.24 million[17] - The company’s total liabilities included short-term borrowings of ¥2 million and accounts payable of approximately ¥1.64 billion[17] Research and Development - Research and development expenses for Q3 2022 amounted to ¥36,541,930.24, a 224.74% increase compared to the same period last year[6] - The R&D expenses accounted for 18.58% of operating revenue, an increase of 12.58 percentage points year-over-year[6] - Research and development expenses for the first three quarters of 2022 totaled CNY 690,730,825.03, compared to CNY 30,337,987.15 in the same period last year[20] Earnings Per Share - The basic earnings per share for Q3 2022 were ¥2.81, up 57.87% from the previous year[6] - The diluted earnings per share for Q3 2022 were also ¥2.81, reflecting a 57.87% increase year-over-year[6] - Basic and diluted earnings per share for the third quarter of 2022 were CNY 34.51, compared to CNY 6.17 in the previous year[22] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥3,935,709,712.99, representing a 1,102.68% increase compared to the same period last year[6] - The cash inflow from operating activities for the first three quarters of 2022 reached ¥6,587,653,959.61, a significant increase from ¥806,134,255.58 in the same period of 2021, representing an increase of approximately 717%[24] - The net cash flow from operating activities was ¥3,935,709,712.99, compared to ¥327,246,097.36 in the previous year, indicating a growth of about 1,103%[24] - The cash inflow from investment activities totaled ¥5,955,062,284.83, up from ¥24,044,618.19 in 2021, marking an increase of approximately 24,757%[25] - The net cash flow from investment activities was -¥3,038,153,230.16, compared to -¥240,821,387.22 in the same period last year, reflecting a deterioration in investment cash flow[25] - The cash inflow from financing activities was ¥300,000.00, while the cash outflow totaled ¥240,701,565.59, resulting in a net cash flow of -¥240,401,565.59[25] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 10,118[13] - The top shareholder, Hangzhou Aixi Holdings, holds 26.87% of the shares, followed by Ling Shisheng with 25.12%[14] Future Plans - The company plans to expand its market presence and invest in new product development[15] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[23] Dividend Distribution - The company has implemented a dividend distribution of ¥3.88 per share and a capital reserve increase of 0.48 shares for every share held[15]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 25%[12]. - The company's operating revenue for the first half of 2022 reached approximately CNY 5.93 billion, representing a year-on-year increase of 1,100.35%[21]. - Net profit attributable to shareholders increased to approximately CNY 2.88 billion, a year-on-year growth of 1,323.67%[20]. - Basic and diluted earnings per share were CNY 46.92, reflecting a significant increase of 968.79% compared to the same period last year[22]. - The total profit for the first half of 2022 was CNY 3,301,922,500.85, compared to CNY 239,082,064.84 in the same period of 2021, marking an increase of approximately 1281%[182]. - The total comprehensive income for the first half of 2022 was CNY 2,905,421,716.33, compared to CNY 202,813,976.49 in the same period of 2021, showing a growth of approximately 1337%[182]. - The company achieved an operating profit of CNY 3,307,808,610.88, compared to CNY 239,100,814.58 in the first half of 2021, representing an increase of about 1282%[182]. - The net cash flow from operating activities increased by 1,424.28% to approximately CNY 3.93 billion[20]. - The company reported a significant increase in sales revenue from RMB 6,045,830,291.26 in the first half of 2022 compared to RMB 589,339,649.92 in the same period of 2021, reflecting an increase of approximately 925%[187]. Research and Development - Research and development expenses increased by 15% year-on-year, totaling RMB 15 million, reflecting the company's commitment to innovation[12]. - The total R&D investment reached ¥654,188,894.79, a significant increase of 3,327.72% compared to ¥19,085,234.29 in the same period last year[52]. - R&D investment accounted for 11.03% of total revenue, up from 3.86% year-on-year, indicating a stronger focus on innovation[52]. - The company has developed over 200 types of colloidal gold products, achieving high sensitivity, specificity, and stability in its testing solutions[35]. - The company has established a comprehensive research and development system, focusing on product iteration and innovation to meet diverse market demands[29]. - The company has obtained 27 new patents during the reporting period, bringing the total to 98 patents, including 14 invention patents[44]. - The company is focusing on technology innovation as its core competitive advantage, with a strong emphasis on market-driven and technology-driven product development[61]. - The company has established a new research and development platform for recombinant antibodies and bioactive enzymes, enhancing product quality and cost control[40]. Market Expansion and Strategy - The company expects a revenue growth forecast of 30% for the second half of 2022, driven by new product launches and market expansion strategies[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by the end of 2023[12]. - The company has established partnerships with three major hospitals to enhance its distribution network and improve service delivery[12]. - The company has established a stable profit model with over 99.25% of sales coming from overseas markets, mainly in North America, Europe, and Oceania[29]. - The company is actively expanding its technology platforms, including immunochromatography, dry biochemical, and chemiluminescence technologies, to ensure comprehensive development from upstream raw materials to diagnostic reagents[63]. Shareholder Commitments and Governance - The company has not proposed any profit distribution or capital reserve transfer for the first half of 2022, focusing on reinvestment strategies[102]. - The controlling shareholder, Aixi Holdings, committed to a 36-month lock-up period for shares post-IPO, ensuring no transfer or management delegation of shares held prior to the issuance[109]. - The company has outlined that any adjustments to the issuance price will occur if there are dividend distributions or capital increases during the lock-up period[111]. - The company has established a strategy to manage shareholding reductions in accordance with the Securities Law and relevant regulations[116]. - The company will ensure that any share reductions comply with the requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[116]. Financial Position and Assets - Total assets increased by 127.30% compared to the end of the previous year, amounting to approximately CNY 7.46 billion[21]. - The company's net assets attributable to shareholders grew by 102.33% compared to the end of the previous year, reaching approximately CNY 5.27 billion[21]. - The company's total liabilities reached RMB 2,143,697,599.18, compared to RMB 657,329,954.33 at the beginning of the period, indicating a substantial rise in financial obligations[174]. - The company's total equity reached CNY 4,911,280,303.98, up from CNY 2,620,275,310.77, representing an increase of approximately 87%[178]. - The company’s total assets at the end of the period were reported at 2,667,200,150, showing an increase from the previous year's 2,639,287,819, which is an increase of approximately 1.8%[195]. Product Development and Innovation - A new product line in the IVD sector is set to launch in Q4 2022, anticipated to contribute an additional RMB 20 million in revenue[12]. - The company has launched new POCT instruments, including blood glucose and ketone analyzers, enhancing its product offerings in chronic disease detection[37]. - The company is actively pursuing the registration and certification of POCT reagents and instruments, enhancing its product portfolio[47]. - The company has made significant advancements in product development, including the introduction of portable urine analyzers and handheld drug testing devices[46]. - The company is focusing on the development of pen-shaped diagnostic products for various infectious diseases, including COVID-19 and monkeypox[70].